New Approaches to Cancer Therapy

Pivotal BioSciences, Inc. is an emerging company dedicated to the development and commercialization of innovative cancer therapies.

Breakthroughs in the basic understanding of the immune system, combined with powerful new biotechnological tools, have provided the foundation for new, rational, and technologically sophisticated approaches to immunotherapy.

The product candidates developed by Pivotalís distinguished founders were discovered at the University of Southern California Keck School of Medicine. Pivotal's strategy is to initiate early-stage clinical trials and then obtain commercialization partners to complete advanced clinical trials, obtain FDA approval, manufacture and market its highly promising drug candidates.

PB101: A low toxicity analog of interleukin-2, an important cytokine already used in cancer immunotherapy

PB103: LEC/mAb, a new fusion protein

PB105: LEC/rituximab, a "bio-better" version of Rituxan®




Pivotal BioSciences, Inc.
8721 Santa Monica Blvd.
Suite 100
Los Angeles, CA 90069

Tel: (310) 734-4551


Pivotal BioSciences, Inc. © 2015. All Rights Reserved.

Site Design by Good Point Web Design